The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years
In 2011 - 2012 years in the Institute of childhood infections followed by an open comparative randomized study of tick-borne encephalitis vaccine EntseVir («Microgen») at a dose of 0.25 ml of the two schemes, planned and emergency in children aged 3 - 17 years. As a reference drug used vaccine FSME-...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2015-04-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/40 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690299201224704 |
|---|---|
| author | S. M. Kharit A. A. Ruleva I. V. Fridman E. P. Nacharova L. A. Alekseeva G. A. Vasil'eva A. A. Vilnic M. V. Ivanova |
| author_facet | S. M. Kharit A. A. Ruleva I. V. Fridman E. P. Nacharova L. A. Alekseeva G. A. Vasil'eva A. A. Vilnic M. V. Ivanova |
| author_sort | S. M. Kharit |
| collection | DOAJ |
| description | In 2011 - 2012 years in the Institute of childhood infections followed by an open comparative randomized study of tick-borne encephalitis vaccine EntseVir («Microgen») at a dose of 0.25 ml of the two schemes, planned and emergency in children aged 3 - 17 years. As a reference drug used vaccine FSME-Immun junior production (Baxter, AG, Austria). The results of clinical studies have shown that Entsevir at a dose of 0.25 ml has a good safety profile, low reactogenicity. Mostly recorded transient local reactions such as pain at the injection site weak degree. Severe reactions and post-vaccination complications were absent. EntseVir has no immunosuppressive, immunopathological action, highly immunogenic and can be recommended for mass prophylaxis tick-borne encephalitis in children 3 - 17 years on two schemes of vaccination (planned with an interval of 60 days and emergency with an interval of 14 days). |
| format | Article |
| id | doaj-art-4b82745ac3de4d6b9472cc01a7b2d3ea |
| institution | DOAJ |
| issn | 2073-3046 2619-0494 |
| language | Russian |
| publishDate | 2015-04-01 |
| publisher | Numikom LLC |
| record_format | Article |
| series | Эпидемиология и вакцинопрофилактика |
| spelling | doaj-art-4b82745ac3de4d6b9472cc01a7b2d3ea2025-08-20T03:21:22ZrusNumikom LLCЭпидемиология и вакцинопрофилактика2073-30462619-04942015-04-01142667210.31631/2073-3046-2015-14-2-66-7239The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 YearsS. M. Kharit0A. A. Ruleva1I. V. Fridman2E. P. Nacharova3L. A. Alekseeva4G. A. Vasil'eva5A. A. Vilnic6M. V. Ivanova7Scientific Research Institute of Children’s InfectionsScientific Research Institute of Children’s InfectionsScientific Research Institute of Children’s InfectionsScientific Research Institute of Children’s InfectionsScientific Research Institute of Children’s InfectionsScientific Research Institute of Children’s InfectionsScientific Research Institute of Children’s InfectionsScientific Research Institute of Children’s InfectionsIn 2011 - 2012 years in the Institute of childhood infections followed by an open comparative randomized study of tick-borne encephalitis vaccine EntseVir («Microgen») at a dose of 0.25 ml of the two schemes, planned and emergency in children aged 3 - 17 years. As a reference drug used vaccine FSME-Immun junior production (Baxter, AG, Austria). The results of clinical studies have shown that Entsevir at a dose of 0.25 ml has a good safety profile, low reactogenicity. Mostly recorded transient local reactions such as pain at the injection site weak degree. Severe reactions and post-vaccination complications were absent. EntseVir has no immunosuppressive, immunopathological action, highly immunogenic and can be recommended for mass prophylaxis tick-borne encephalitis in children 3 - 17 years on two schemes of vaccination (planned with an interval of 60 days and emergency with an interval of 14 days).https://www.epidemvac.ru/jour/article/view/40клещевой энцефалитвакцинацияэнцевирtick-borne encephalitisvaccinationentsevir |
| spellingShingle | S. M. Kharit A. A. Ruleva I. V. Fridman E. P. Nacharova L. A. Alekseeva G. A. Vasil'eva A. A. Vilnic M. V. Ivanova The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years Эпидемиология и вакцинопрофилактика клещевой энцефалит вакцинация энцевир tick-borne encephalitis vaccination entsevir |
| title | The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years |
| title_full | The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years |
| title_fullStr | The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years |
| title_full_unstemmed | The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years |
| title_short | The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years |
| title_sort | results of an open randomized comparative clinical study to assess the reactogenicity safety and immunogenicity of the vaccine entsevir in children aged 3 to 17 years |
| topic | клещевой энцефалит вакцинация энцевир tick-borne encephalitis vaccination entsevir |
| url | https://www.epidemvac.ru/jour/article/view/40 |
| work_keys_str_mv | AT smkharit theresultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT aaruleva theresultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT ivfridman theresultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT epnacharova theresultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT laalekseeva theresultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT gavasileva theresultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT aavilnic theresultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT mvivanova theresultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT smkharit resultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT aaruleva resultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT ivfridman resultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT epnacharova resultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT laalekseeva resultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT gavasileva resultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT aavilnic resultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years AT mvivanova resultsofanopenrandomizedcomparativeclinicalstudytoassessthereactogenicitysafetyandimmunogenicityofthevaccineentsevirinchildrenaged3to17years |